TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25451890

Group type: EXPERIMENTAL
Intervention: Miglitol (50mg three times a day)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Sitagliptin (50mg once a day)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Combination of miglitol and sitagliptin (M+S)
Number of subjects: 41
Study: 22061864

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) 5 mg infusion
Number of subjects: 265

Group type: COMPARATOR
Intervention: Risedronate (RIS) 5 mg oral daily
Number of subjects: 265
Study: 19758359

Group type: EXPERIMENTAL
Intervention: Alogliptin 12.5 mg
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg
Number of subjects: 390

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study: 18173915

Group type: EXPERIMENTAL
Intervention: Exercise training group (n = 35) performing 3 sessions per week of aquatic training (32 degrees C) for 16 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (n = 25) of healthy women matched for age, weight, body mass index, and educational and physical activity levels
Number of subjects: 60
Study: 12921554

Group type: EXPERIMENTAL
Intervention: Implanon
Number of subjects: 100

Group type: COMPARATOR
Intervention: Norplant
Number of subjects: 100
Study: 10866439

Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: Oseltamivir 150 mg
Number of subjects: 726

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg (in patients treated within 24 h of symptom onset)
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: Oseltamivir 150 mg (in patients treated within 24 h of symptom onset)
Number of subjects: 726

Group type: COMPARATOR
Intervention: Placebo (in patients treated within 24 h of symptom onset)
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 726
Study: 9383256

Group type: EXPERIMENTAL
Intervention: Cetirizine treatment for 4 weeks during pollen season
Number of subjects: 20
Study: 1586708

Group type: EXPERIMENTAL
Intervention: Lower-dose methylprednisolone (LDM)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Higher-dose methylprednisolone (HDM)
Number of subjects: 68
Study: 3709398

Group type: EXPERIMENTAL
Intervention: 50 g glucose
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 2
Study: 31096275

Group type: EXPERIMENTAL
Intervention: Endocuff-assisted colonoscopy (EAC)
Number of subjects: 711

Group type: COMPARATOR
Intervention: Cap-assisted colonoscopy (CAC)
Number of subjects: 711
Study: 28317149

Group type: EXPERIMENTAL
Intervention: Finasteride arm
Number of subjects: 1157
Study: 26152562

Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg, then 90 mg BID for 7-9 days)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Clopidogrel (600 mg, then 75 mg QD for 7-9 days)
Number of subjects: 34
Study: 24105694

Group type: EXPERIMENTAL
Intervention: PegIFNa2a at 90 μg/week
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: PegIFNa2a at 45 μg/week
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Imatinib at 400 mg with PegIFNa2a at 90 μg/week
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Imatinib at 400 mg with PegIFNa2a at 45 μg/week
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Imatinib at 400 mg with PegIFNa2a at 90 μg/week after dose amendment
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Imatinib at 400 mg with PegIFNa2a at 45 μg/week after dose amendment
Number of subjects: 221
Study: 21986118

Group type: EXPERIMENTAL
Intervention: Preoperative insertion of an intra-aortic balloon pump (IABP)
Number of subjects: 232

Group type: COMPARATOR
Intervention: OPCAB alone
Number of subjects: 232
Study: 19383882

Group type: EXPERIMENTAL
Intervention: Special Intervention (SI)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Minimal Intervention (MI)
Number of subjects: 174
Study: 17875652

Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation (ECMO)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group from original UK ECMO trial
Number of subjects: 106
Study: 15015441

Group type: EXPERIMENTAL
Intervention: Qingre Cuochuang tablet (QCT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Western medicine (including antisterone, tetracycline, and metronidazole)
Number of subjects: 60
Study: 11720460

Group type: EXPERIMENTAL
Intervention: Question prompt sheet provided to patients prior to consultation
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Question prompt sheet used proactively by the doctor
Number of subjects: 318

Group type: COMPARATOR
Intervention: Question prompt sheet provided to patients
Number of subjects: 318
Study: 9137156

Group type: EXPERIMENTAL
Intervention: Closed technique (primary closure with interrupted vertical mattress skin sutures)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Open technique (conventional packing)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Closed technique
Number of subjects: 61
Study: 8108758

Group type: EXPERIMENTAL
Intervention: Cryotherapy (using liquid nitrogen)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Trichloracetic acid
Number of subjects: 86
Study: 3685399

Group type: EXPERIMENTAL
Intervention: Mefenamic acid, 500 mg three times daily during menses (n = 8)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Progesterone-impregnated coil releasing 65 micrograms progesterone daily (n = 8)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Danazol, 200 mg daily (n = 6)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Norethisterone, 5 mg twice daily from day 15‐25 of the cycle (n = 8)
Number of subjects: 30
Study: 29609480

Group type: EXPERIMENTAL
Intervention: Pooled yoga intervention (high, moderate, low frequency)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Guided walking
Number of subjects: 375

Group type: COMPARATOR
Intervention: Health education
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Moderate frequency yoga
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: High frequency yoga
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Low frequency yoga
Number of subjects: 375
Study: 31435739

Group type: EXPERIMENTAL
Intervention: Rocuronium Maruishi (0.9 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rocuronium MSD (0.9 mg/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rocuronium Maruishi
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rocuronium MSD
Number of subjects: 60
Study: 28740251

Group type: COMPARATOR
Intervention: DTS shape 'C'
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: DTS shape '1'
Number of subjects: 300

Group type: COMPARATOR
Intervention: DTS shape 'Г'
Number of subjects: 300
Study: 25733160

Group type: EXPERIMENTAL
Intervention: Joint engagement
Number of subjects: 25
Study: 23914911

Group type: EXPERIMENTAL
Intervention: Side-alternating vibration (SAV) training for 9 weeks, 3 sessions per week, 10 x 15-second isometric contractions with 30-second active rest on SAV plate (acceleration = 0.91-16.3g)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 21
Study: 21297502

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 10305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10305
Study: 19471183

Group type: EXPERIMENTAL
Intervention: Yi-Gan San (YGS) at an average daily dosage of 6.7 +/- 2.5 g (range, 2.5-7.5 g)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (YGS-free)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study: 16505594

Group type: EXPERIMENTAL
Intervention: Probucol (500 mg/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 36
Study: 14704543

Group type: EXPERIMENTAL
Intervention: T-Flux implant
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healon GV
Number of subjects: 20
Study: 11445760

Group type: EXPERIMENTAL
Intervention: CHAMPS intervention to increase physical activity
Number of subjects: 249

Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 249
Study: 9744846

Group type: EXPERIMENTAL
Intervention: Self-administered questionnaires (SAQs)
Number of subjects: 1877

Group type: COMPARATOR
Intervention: Interviewer questioning
Number of subjects: 1877
Study: 7851034

Group type: EXPERIMENTAL
Intervention: Blood pump flow rate of 200 cc/min
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Blood pump flow rate of 500 cc/min
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Blood pump flow rates (QB)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 14-gauge needles
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Blood pump flow rates beyond 300 cc/min
Number of subjects: 16
Study: 3289598

Group type: COMPARATOR
Intervention: Atenolol 50 mg twice daily alone
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg plus nifedipine 20 mg each twice daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg plus nifedipine 40 mg each twice daily
Number of subjects: 25
Study: 29947328

Group type: EXPERIMENTAL
Intervention: Standard care with pressure garments
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard care comprising scar management techniques (massage, moisturiser, silicone treatment, stretching)
Number of subjects: 88
Study: 28753161

Group type: EXPERIMENTAL
Intervention: 6-week prescribed home-based exercise intervention (INT; n = 13) - 4 × 45-min moderate-intensity arm-crank exercise sessions per week
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (CON; n = 8)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 6-week prescribed home-based exercise intervention (INT; n = 13)
Number of subjects: 21
Study: 25201759

Group type: EXPERIMENTAL
Intervention: Wildflower honey and milk mixture (10ml honey + 90ml milk) for three evenings
Number of subjects: 134

Group type: COMPARATOR
Intervention: Dextromethorphan (DM) or Levodropropizine (LDP) adjusted for age
Number of subjects: 134
Study: 23457535

Group type: EXPERIMENTAL
Intervention: Continuous combination antiretroviral therapy (cART)
Number of subjects: 144
Study: 21273177

Group type: EXPERIMENTAL
Intervention: Concurrent docetaxel (75 mg/m² I.V.) followed by bortezomib (1.6 mg/m² I.V. on days 1 and 8)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Sequential docetaxel (75 mg/m² I.V.) followed by bortezomib (1.6 mg/m² I.V. on days 2 and 8)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Both arms (CON and SEQ)
Number of subjects: 81
Study: 19446148

Group type: EXPERIMENTAL
Intervention: 150 mg monthly oral ibandronate
Number of subjects: 1760

Group type: COMPARATOR
Intervention: 70 mg weekly oral alendronate
Number of subjects: 1760

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 1760
Study: 16368347

Group type: EXPERIMENTAL
Intervention: Glyceril‐trinitrate/verapamil (GV) solution
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Papaverine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 100
Study: 15197428

Group type: EXPERIMENTAL
Intervention: 60 mg intra-articular ketorolac
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 10 cc intra-articular bupivacaine 0.25%
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 1 mg intra-articular morphine diluted in 10 cc saline
Number of subjects: 80

Group type: COMPARATOR
Intervention: 10 cc saline
Number of subjects: 80
Study: 11071343

Group type: COMPARATOR
Intervention: Traditional care system using a surfactant cleaner
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: One-step chemical care system
Number of subjects: 66

Group type: COMPARATOR
Intervention: Traditional method of computing the BOZR
Number of subjects: 66

Group type: COMPARATOR
Intervention: Corneal topometry
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Newly developed guide for TD selection
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Overall success rate of fitting high Dk RGP contact lenses
Number of subjects: 66
Study: 9176662

Group type: EXPERIMENTAL
Intervention: Colgate Total (triclosan/copolymer/SLS/propylene glycol)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Solidox G (triclosan/zinc citrate/SLS/polyethylene glycol)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Solidox F (SLS/polyethylene glycol)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Zendium (non‐ionic detergent)
Number of subjects: 19
Study: 2030189

Group type: EXPERIMENTAL
Intervention: Cognitive therapy plus standard inpatient treatment (pharmacotherapy and milieu management)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard inpatient treatment (pharmacotherapy and milieu management)
Number of subjects: 39
Study: 7021992

Group type: EXPERIMENTAL
Intervention: Caerulein (20 ng/kg) injected intravenously before oral glucose load
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control tests without caerulein application
Number of subjects: 17
Study: 29508046

Group type: EXPERIMENTAL
Intervention: Tibial nerve stimulation (GTNS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training associated with behavioral therapy (GPFMT)
Number of subjects: 40
Study: 28692723

Group type: EXPERIMENTAL
Intervention: Deutetrabenazine
Number of subjects: 37
Study: 28718495

Group type: COMPARATOR
Intervention: Single HIV and single syphilis rapid diagnostic tests (Arm A)
Number of subjects: 2214

Group type: EXPERIMENTAL
Intervention: Dual HIV and syphilis rapid diagnostic tests (Arm B)
Number of subjects: 2214
Study: 22947108

Group type: EXPERIMENTAL
Intervention: Group CBT
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Self-Help CBT
Number of subjects: 20
Study: 21912128

Group type: EXPERIMENTAL
Intervention: Twice weekly supervised brushing with a self-applied gel containing 12,500 ppm fluoride
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: Weekly supervised use of the gel
Number of subjects: 1075

Group type: COMPARATOR
Intervention: Usual oral hygiene care (Control)
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: Gel applications (at least 60 times over 2 years)
Number of subjects: 1075
Study: 19239660

Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate (SFC) 50/100 microg bd
Number of subjects: 321

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 200 microg bd
Number of subjects: 321
Study: 16681480

Group type: EXPERIMENTAL
Intervention: Testosterone propionate (2 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 15566420

Group type: EXPERIMENTAL
Intervention: 6 mg sumatriptan
Number of subjects: 24
Study: 11406907

Group type: EXPERIMENTAL
Intervention: Low-dose perindopril 2 mg plus indapamide 0.625 mg (P/I)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Losartan 50 mg (L50)
Number of subjects: 277
Study: 9728841

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution (saline)
Number of subjects: 20
Study: 7876403

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (40 mg, 100 mg, 250 mg, 500 mg)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Methylprednisolone suleptanate (40 mg, 100 mg, 250 mg, 500 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Comparison of both prodrugs
Number of subjects: 29
Study: 3277436

Group type: EXPERIMENTAL
Intervention: carteolol 1%
Number of subjects: 98

Group type: COMPARATOR
Intervention: timolol 0.25%
Number of subjects: 98
Study: 29744608

Group type: EXPERIMENTAL
Intervention: TPB-based educational program administered over 1 month
Number of subjects: 120

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 120
Study: 27993154

Group type: EXPERIMENTAL
Intervention: Stempeucel® (25 million cells)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Stempeucel® (50 million cells)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Stempeucel® (75 million cells)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Stempeucel® (150 million cells)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 24727884

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 11080

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 11080
Study: 23047956

Group type: EXPERIMENTAL
Intervention: Computerised cognitive behaviour therapy (CCBT)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control condition (waitlist)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Patient ratings of treatment
Number of subjects: 88
Study: 20669558

Group type: EXPERIMENTAL
Intervention: Lymphadenectomy (complete including external and primary iliac and lumboaortic chains up to the left renal vein)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Number of subjects: 0
Study: 19385464

Group type: EXPERIMENTAL
Intervention: Intraaortic balloon pump (IABP) insertion
Number of subjects: 106
Study: 16649862

Group type: EXPERIMENTAL
Intervention: Implicit theories of ability
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 x 2 achievement goal framework
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived competence
Number of subjects: 0
Study: 12795541

Group type: EXPERIMENTAL
Intervention: Frame Model of Preadolescent Empowerment intervention
Number of subjects: 0
Study: 11000331

Group type: EXPERIMENTAL
Intervention: PHHI patients
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 31
Study: 8838180

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (750 mg twice daily)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 8470726

Group type: EXPERIMENTAL
Intervention: pyrimethamine, sulfadiazine, and corticosteroids
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: clindamycin, sulfadiazine, and corticosteroids
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: trimethoprim, sulfamethoxazole and corticosteroids
Number of subjects: 149

Group type: COMPARATOR
Intervention: untreated patients
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: all patients
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: pyrimethamine
Number of subjects: 149
Study: 3769399

Group type: EXPERIMENTAL
Intervention: Glucose infusion at a rate of 1.1 mmol/min
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 14
Study: 30358731

Group type: EXPERIMENTAL
Intervention: Intravaginal 0.50% DHEA (6.5 mg)
Number of subjects: 482
Study: 26627728

Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 137

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 137
Study: 24872223

Group type: EXPERIMENTAL
Intervention: Calcium intake ranging from 600 to 2300 mg/d
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Calcium intake
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Serum alkaline phosphatase
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Other variables measured (urine N-telopeptide of type I collagen/creatinine ratio, Tanner score, serum parathyroid hormone, 25-hydroxyvitamin D, weight, height, body mass index)
Number of subjects: 40
Study: 24324573

Group type: EXPERIMENTAL
Intervention: ART initiation
Number of subjects: 812
Study: 20876929

Group type: EXPERIMENTAL
Intervention: Post-mastectomy group (Group 1)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (Group 2)
Number of subjects: 51
Study: 18929735

Group type: EXPERIMENTAL
Intervention: Conventional regimen (13 cycles with 21 days of treatment + 7 days without hormones)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Extended-cycle regimen (4 extended cycles with 84 days of continuous administration of EE/DNG, followed by a hormone-free interval of 7 days)
Number of subjects: 59
Study: 16622332

Group type: EXPERIMENTAL
Intervention: Gastric emptying time measured using half emptying time (T1/2) in GER-positive patients (grade 2)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Gastric emptying time measured using half emptying time (T1/2) in GER-negative patients
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Number of reflux episodes
Number of subjects: 108
Study: 12809074

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU; 120 mg daily, for 3 months)
Number of subjects: 48

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 48
Study: 11012954

Group type: EXPERIMENTAL
Intervention: Imaging Method (IM)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: SmartNeedle (SM)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Landmarks Method (LM)
Number of subjects: 45

Group type: COMPARATOR
Intervention: All methods (IM, SM, LM)
Number of subjects: 45
Study: 8781903

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily for 8 weeks
Number of subjects: 152

Group type: COMPARATOR
Intervention: Triple therapy: bismuth subsalicylate 600 mg three times daily for 8 weeks, amoxicillin 500 mg twice daily, and tinidazole 1000 mg twice daily for the first 10 days
Number of subjects: 152

Group type: COMPARATOR
Intervention: Omeprazole group
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Triple therapy group
Number of subjects: 152

Group type: COMPARATOR
Intervention: H. pylori positive patients
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: H. pylori negative patients
Number of subjects: 152
Study: 1458662

Group type: EXPERIMENTAL
Intervention: 0.25% amorolfine cream formulation applied to intact skin (n = 6)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.25% amorolfine cream formulation applied to stripped skin (n = 6)
Number of subjects: 12
Study: 6419315

Group type: EXPERIMENTAL
Intervention: Polyvalent pseudomonas vaccine (PEV‐01)
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Antipseudomonas human immunoglobulin
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: PEV‐01 plus immunoglobulin
Number of subjects: 746

Group type: COMPARATOR
Intervention: No immunologic prophylaxis
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Immunologic regimens (PEV‐01, immunoglobulin)
Number of subjects: 746
Study: 30828771

Group type: EXPERIMENTAL
Intervention: Microdosed FXaI cocktail (rivaroxaban, apixaban, edoxaban at 100 µg total)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Microdosed FXaI cocktail with ketoconazole
Number of subjects: 18
Study: 30252519

Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioral treatment (CBT)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard outpatient treatment
Number of subjects: 92
Study: 27235849

Group type: EXPERIMENTAL
Intervention: Ibuprofen (1200mg/d)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19